Evidence map›Paper›PMID 34906838›Full record

ArticleBiosensors & bioelectronics2022

Instrument-free, CRISPR-based diagnostics of SARS-CoV-2 using self-contained microfluidic system.

Ziyue Li, Xiong Ding, Kun Yin, Lori Avery, Enrique Ballesteros, Changchun Liu

Open access · greenAbstract read
In one paragraph

Article in Biosensors & bioelectronics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 1 pooled it
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 1 synthesis or guideline pooled it, 136 citations in OpenAlex.

  1. Pooled it
  2. CRISPR-Programmable Nanoparticle Transport in Salt-Gated Porous Media for Visual DNA Detection.Chemical engineering journal (Lausanne, Switzerland : 1996) · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Ziyue LiDepartment of Biomedical Engineering, University of Connecticut Health Center, 263 Farmington Ave., Farmington, CT, 06030, United States; Department of Biomedical Engineering, University of Connecticut, 260 Glenbrook Road, Storrs, CT, 06029, United States.
Xiong DingDepartment of Biomedical Engineering, University of Connecticut Health Center, 263 Farmington Ave., Farmington, CT, 06030, United States.
Kun YinDepartment of Biomedical Engineering, University of Connecticut Health Center, 263 Farmington Ave., Farmington, CT, 06030, United States.
Lori AveryDepartment of Pathology and Laboratory Medicine, University of Connecticut Health Center, Farmington, CT, 06030, United States.
Enrique BallesterosDepartment of Pathology and Laboratory Medicine, University of Connecticut Health Center, Farmington, CT, 06030, United States.
Changchun LiuDepartment of Biomedical Engineering, University of Connecticut Health Center, 263 Farmington Ave., Farmington, CT, 06030, United States. Electronic address: chaliu@uchc.edu.
UConn Health · USUniversity of Connecticut · US

Funding

Asymmetric CRISPR Approach for Nucleic Acid QuantificationR01EB023607 · NIBIB · UNIVERSITY OF PENNSYLVANIA · PI Changchun Liu · 2017 to 2026
$2.4M
Self-Powered Sample Concentrating and CRISPR-based Biosensing for Moile HIV-1 RNA DetectionR61AI154642 · NIAID · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI LIU, CHANGCHUN · 2020 to 2022
$1.4M
NIAID NIH HHS R61 AI154642NIBIB NIH HHS R01 EB023607
6 · The paper itself

Abstract

Rapid and sensitive detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical for early diagnostics and timely medical treatment of coronavirus disease 2019 (COVID-19). However, current detection methods typically rely on expensive and bulky instrumentation. Here, we developed a simple, sensitive, instrument-free, CRISPR-based diagnostics of SARS-CoV-2 using a self-contained microfluidic system. The microfluidic chip integrates isothermal amplification, CRISPR cleavage, and lateral flow detection in a single, closed microfluidic platform, enabling contamination-free, visual detection. To simplify the operation and transportation of the device, we lyophilized the CRISPR reagents in the reaction chamber and pre-stored the liquid solutions in blisters. We employed a low-cost, portable hand warmer to incubate the microfluidic chip without the need for electricity. The self-contained microfluidic system can detect down to 100 copies of SARS-CoV-2 RNA. Further, we clinically validated our method by detecting 24 COVID-19 clinical nasopharyngeal swab samples, achieving excellent sensitivity (94.1%), specificity (100%), and accuracy (95.8%). This simple, sensitive, and affordable microfluidic system represents a promising tool for point-of-care diagnostics of COVID-19 and other infectious diseases.

Indexed as

Biosensing TechniquesCOVID-19CRISPR-Cas SystemsHumansMicrofluidicsNucleic Acid Amplification TechniquesRNA, ViralSARS-CoV-2Sensitivity and SpecificityRNA, ViralCRISPR-Cas12aHand warmerInstrument-free molecular diagnosticsSARS-CoV-2 detectionSelf-contained microfluidic chip

Identifiers

PMID34906838
PMCPMC8653405
OpenAlexW4200289441

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.